Humira is used to treat certain inflammatory conditions. It’s mainly covered by Medicare Part D when self-administered or, more rarely, by Part B when administered by a doctor. Humira ...

The availability of Humira biosimilars potentially affects a vast number of patients and healthcare professionals. Our team of clinicians explored all of the different biosimilars set to enter the ...

European regulators have backed a new Humira biosimilar for approval, setting up a four-way race for the blockbuster’s market share later this year between Amgen, Boehringer Ingelheim ...

Opinions expressed by Forbes Contributors are their own. Joshua Cohen is a Boston-based writer who covers health policy. In a unique challenge to drug makers, the Dutch Pharmaceutical ...

As of today, July 1st, Cyltezo (adalimumab-adbm) is commercially available in the U.S. It is the first and thus far only therapeutically interchangeable Humira-referenced biosimilar approved by ...

Some parts of Medicare, including Part B and Part D, may cover the approved drug Humira (adalimumab). However, some Medicare Advantage plans may also offer coverage. Humira contains the active ...